All lobbying filings

THE MCMANUS GROUP

THE MCMANUS GROUP filed a Q3 report for GENENTECH on October 20, 2026, reporting $50,000 in lobbying income.

Lobbying for GENENTECH

All filings by THE MCMANUS GROUP · Everything GENENTECH has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

JOHN MCMANUS

Previously held: Staff Director W&M Health Subcommittee; LA, Rep. Bill Thomas

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Medicare/Medicaid

Access and reimbursement in Medicare Parts B and D. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs, including Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 4299). Policies related to the Most Favored Nation Drug Pricing Model.

Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to the SECURE 340B Act (H.R.9599).

Taxation/Internal Revenue Code

Issues related to tax exempt hospitals and charity care. Issues related to the Tax Exempt Hospital Transparency Act (H.R. 9504).

Bills named in this filing 3

H.R. 4299
Protecting Patient Access to Cancer and Complex Therapies Act
H.R. 9599
SECURE 340B Act
H.R. 9504
Tax Exempt Hospital Transparency Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.